VISTAGEN THERAPEUTICS, INC. Long-Term Debt, Maturity, after Year Five
VISTAGEN THERAPEUTICS, INC. (VTGN) had Long-Term Debt, Maturity, after Year Five of $71.60 thousand as of 2013-03-31, per its 10-K filed 2013-07-18.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2013-07-18
- 2013-03-31: Long-Term Debt, Maturity, after Year Five $71.60K.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2013-03-31 | $71.60K 10-K · filed 2013-07-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |